We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
12
1 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Completed
7
58.3%
Enrolling By Invitation
1
8.3%
Recruiting
Terminated
2
16.7%
Unknown
No approval data available
- The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved the first-ever human trial of regenerative cell therapy for sensorineural hearing loss, marking a significant milestone in auditory medicine. - Rinri Therapeutics' Rincell-1 therapy is designed to regenerate damaged auditory neurons, targeting a condition for which no current treatment exists beyond symptom management. - The randomized, open-label trial will involve 20 patients across three UK research centers, with clinical proof-of-concept data expected within 12 months of trial initiation. - The therapy represents a potential breakthrough for treating neural hearing loss by replacing damaged sensory cells in the inner ear to restore hearing function.